Dexmedetomidine on Segmental EEG Power Spectra

The Effects of Dexmedetomidine on Segmental EEG Power Spectra Activity Under Propofol-based Anesthesia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03515876

Enrollment

Registered

2018-05-04

Start date

2018-04-19

Completion date

2019-07-31

Last updated

2019-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, EEG Power Spectra

Brief summary

To compare the EEG power spectra activity during propofol-based anesthesia in the presence or absence of dexmedetomidine in patients undergoing hysteroscopic examination and surgery to determine whether the addition of dexmedetomidine will induce better sleep-like anesthesia status.

Detailed description

Three groups of patients undergoing hysteroscopic examination and surgery will be studied: 1) control group, patients will receive propofol intravenous infusion to provide anesthesia; 2) dexmedetomidine 0.5 microgram/kg group. This dexmedetomidine dose is infused within 10 min and then the use of propofol for anesthesia; and 3) dexmedetomidine 1 microgram/kg group. This dexmedetomidine dose is infused within 10 min and then the use of propofol for anesthesia. Each group will have 20 patients. General conditions including blood pressure, respiration, and heart rates will be recorded. EEG power spectra activity will be recorded no-invasively by a Narcotrend EEG monitor.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists Physical status I to II grade. * body mass index 18 to 25 kg/m2 * no vision or hearing impairment * will receive general anesthesia

Exclusion criteria

* with psychological or mental diseases * with neurological diseases * treating with steroids or with alcohol dependence.

Design outcomes

Primary

Measure	Time frame	Description
EEG power spectra	From prior to anesthesia to 10 min after anesthesia.	EEG power spectra monitored no-invasively by Narcotrend

Secondary

Measure	Time frame	Description
Blood pressure	From prior to anesthesia to 10 min after anesthesia.	Blood pressure monitored no-invasively
Respiration	From prior to anesthesia to 10 min after anesthesia.	Monitored no-invasively
Heart rates	From prior to anesthesia to 10 min after anesthesia.	Monitored no-invasively

Countries

China

Contacts

Primary ContactZhi Wang, MD

wwzz1898@163.com13622740039

Outcome results